Our Services
Medical Information
Helpful Resources
Published on: 4/21/2026
Several factors determine how a neuropathy diagnosis affects your life insurance premiums, including the underlying cause, severity, stability, and effectiveness of your treatment. Mild, well-controlled neuropathy often qualifies for preferred or standard rates, while more severe or complicated cases typically lead to table ratings and higher premiums.
See below for a detailed breakdown of underwriting criteria, tips to improve your insurability, and important next steps in your healthcare journey.
A diagnosis of neuropathy can raise questions about your insurability and premium costs. "Neuropathy and life insurance" is a topic many applicants research when they find tingling, numbness, or pain in their hands and feet. In this guide, we'll explain:
We'll also suggest a free, online symptom check for Diabetic Neuropathy if you suspect that high blood sugar might be the underlying cause of your nerve symptoms. Always speak to a doctor about anything that could be life-threatening or serious.
Neuropathy, or peripheral neuropathy, refers to damage of the peripheral nerves—the network that carries messages between your brain, spinal cord, and the rest of your body. Symptoms can include:
Common causes include diabetes, chemotherapy, autoimmune disorders, infections, vitamin deficiencies, and certain medications.
Life insurance premiums are based on risk. Underwriters review:
A pre-application phone interview and attending physician statement (APS) may be ordered. If you disclose a neuropathy diagnosis (or labs suggest nerve damage), the insurer evaluates how that condition affects your overall mortality and morbidity risk.
When assessing neuropathy, insurers focus on:
Neuropathy does not automatically disqualify you from life insurance, but it often leads to substandard ("rated") offers. Typical impacts include:
Below is an example of how table ratings work:
| Risk Class | Typical Rating | Premium Impact |
|---|---|---|
| Preferred Plus | Standard rates | 0% increase |
| Standard | Standard rates | 0% increase |
| Table A | Mild rating | +25% |
| Table B | Moderate rating | +50% |
| Table C–H | Severe rating | +75% to +200% |
Gather Documentation
Show Effective Management
Demonstrate Stability
Consider Multiple Quotes
Explore Alternative Products
Effective management of your neuropathy can translate into more favorable life insurance rates. Actions to consider include:
If you're experiencing numbness, tingling, or burning sensations and suspect high blood sugar may be the culprit, taking a quick assessment can help you understand whether Diabetic Neuropathy might be affecting you—it's free and takes just a few minutes.
Always speak to a doctor about concerns that could indicate a serious underlying condition. Early diagnosis and treatment not only improve quality of life but may also positively influence your life insurance application.
"Neuropathy and life insurance" is a nuanced topic. A neuropathy diagnosis doesn't necessarily block you from coverage, but it can lead to higher premiums or special ratings. Key takeaways:
By taking proactive steps—managing your health, organizing records, and consulting both your doctor and an experienced insurance agent—you can improve your chances of securing life insurance at a competitive rate. Remember: always speak to a healthcare professional about any serious or life-threatening symptoms.
(References)
* Gouty D, Patel H, Tang Y, Lin N, Pan G. Economic burden of chronic inflammatory demyelinating polyneuropathy (CIDP) in the US: a retrospective claims analysis. J Manag Care Spec Pharm. 2021 Jan;27(1):37-46. PMID: 33499427.
* Benkhadra M, Alahmar A, Alahmar A, Noureddine M, Alouani R, Khouzani S, Ghosn J, Albitar O. The direct and indirect costs of chronic inflammatory demyelinating polyneuropathy: a critical review of the literature. J Manag Care Spec Pharm. 2023 Apr;29(4):396-407. PMID: 37048126.
* Ye M, Li M, Xu Y, Li C, Wang J, Shi T. Economic burden of chemotherapy-induced peripheral neuropathy: a systematic review. J Cancer Surviv. 2023 Apr;17(2):494-507. PMID: 36720760.
* Al-Hassany SM, Bliwise DL, Malik A, Qureshi AI. Economic burden of diabetic neuropathy in the United States: A systematic review. J Diabetes Complications. 2018 Sep;32(9):885-891. PMID: 30146313.
* Mehra M, LaGuardia J, Pan G, Gabriel S. Real-world healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy in the United States. J Med Econ. 2018 Nov;21(11):1114-1123. PMID: 30048259.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.